Drug intelligence / Profile preview

allogeneic fecal microbiota

Development stage
Approved
Lead developer
Ferring Pharmaceuticals
Modality
Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration
Oral, Rectal, Nasogastric, Nasoduodenal, Intraduodenal
01

Overview

Allogeneic fecal microbiota is a therapeutic approach that involves transplanting fecal matter from a healthy donor into the gastrointestinal tract of a recipient to restore gut microbiota diversity and function. The procedure directly modifies the host gut microbiome composition to restore diversity and gut homeostasis. It can be delivered via various routes including the upper gastrointestinal tract (using esophagogastroduodenoscopy, nasogastric or nasoduodenal tube, oral capsule) or lower gastrointestinal tract (via colonoscopy or enema). The source of fecal material is from a related or unrelated healthy donor (allogeneic), as opposed to autologous FMT where the patient's own previously collected stool is used.

Brand names
REBYOTAVOWST
Other names
FMTfecal microbiota transplantationfecal microbiota transferstool transplantbacteriotherapyintestinal microbiota transplantfecal microbiota live-jslm

Beyond the preview

Go deeper on allogeneic fecal microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on allogeneic fecal microbiota.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call